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Abstract
Background: Colorectal cancer is the third most-common cancer and the second most-common cause of cancer
related death in UK. Although chemotherapy plays significant role in the treatment of colorectal cancer, morbidity
and mortality due to drug resistance and cancer metastasis are yet to be eliminated. Recently, doxycycline has
been reported to have cytotoxic and anti-proliferating properties in various cancer cells. In this study, whether
doxycycline was apoptosis threshold lowering agent in colorectal cancer cells by targeting mitochondria was
answered.
Results: This study showed dose-dependent cytotoxic effects of cisplatin, oxaliplatin and doxycycline in HT29
colorectal cancer cells. Doxycycline showed inhibition of cytochrome-c-oxidase activity in these cells over a time-
period. The pre-treatment of doxycycline reported statistically significant increased cytotoxicity of cisplatin and
oxaliplatin compared to cisplatin and oxaliplatin alone. The caspase studies revealed significantly less expression
and activity of caspase 3 in HT29 cells pre-treated with doxycycline compared to the cells treated with cisplatin
and oxaliplatin alone.
Conclusions: It was concluded that doxycycline lowered the apoptotic threshold in HT 29 cells by targeting
mitochondria. This also raised possible caspase-independent mechanisms of apoptosis in HT29 cells when
pre-treated with doxycycline however this needs further research work.
Background
Tetracyclines (TCNs) have long been used widely in
clinical practice as antibiotics in various bacterial, myco-
plasma, chlamydiae, rickettsiae and protozoan infections.
Their main mechanism of action involves inhibition of
protein synthesis by restricting binding of aminoacyl
t-RNA to 30 S ribosomes. TCNs are believed to inter-
fere in mitochondrial protein synthesis that let to the
discovery of other effects of TCNs independent of their
antimicrobial actions[1]. Recently, a renewed interest in
study of TCNs has evolved due to their ability to inhibit
matrix metalloproteinases (MMPs) in various cancers
such as prostate[2], melanoma[3], osteosarcoma[4],
breast[5], leukaemia [6] and colorectal cancers[7]. Some
of TCNs have been shown to work as apoptotic indu-
cers[8]. Despite TCNs’ emerging role as anti-invasive
and anti-proliferative drugs in cancer treatment, their
apoptotic mechanisms are yet to be precisely defined.
Apoptosis is the mechanism by which chemotherapeu-
tic agents induce cancer cell death[9]. There are two
main mechanisms of apotptosis; the intrinsic and extrin-
sic pathways. Caspases, the proteolyic enzymes, cysteine
proteases, play an essential role in execution of apopto-
sis[10]. In the extrinsic pathway, upon apoptotic stimu-
lus, the death receptors bind to adaptor proteins and
pro-caspases forming death initiating signal complex
(DISC), which either lead to activation of caspases or
cleavage of Bcl-2 family members causing apoptosis and
cell death[11,12]. In the intrinsic pathway, the apoptotic
stimulus activates Bcl-2 family members’ protein synth-
esis, which causes cytochrome c release from mitochon-
dria. The released cytochrome c, along with adaptor
protein and pro-caspases forms an apoptosome and
leads to release of activated caspases inducing apoptosis
and cell death[11,12].
Colorectal cancer is the third most common cancer in
males and the second most common cancer in females.
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Apart from the surgical option, chemotherapy and
radiotherapy also play significant roles in the treatment
of the colorectal cancer especially in advanced or meta-
static disease. Different chemical agents including plati-
num agents have been used in various trials to improve
the outcome of colorectal cancer treatment however
problems of metastasis and recurrence are yet to be
eliminated.
Doxycycline, one of the most widely used TCNs in
clinical practice, is a long acting orally administered che-
mical agent. Apart from its antibiotic properties, it has
been shown to inhibit cell proliferation and invasion
and to induce apoptosis in colorectal cancer cells[14,15].
As doxycycline restricts oxidative phosphorylation by
inhibition of mitochondrial protein synthesis and thus
reduces ATP synthesis, the effects of combination ther-
apy of doxycycline with cisplatin and oxaliplatin on HT
29 colorectal cancer cell line were investigated in this
study in an attempt to improve the drug efficacy and to
reduce drug resistance.
Results
Cytotoxicity of Drugs
The cytotoxicity studies revealed dose dependent cyto-
toxic effects of cisplatin, oxaliplatin and doxycycline on
HT 29 cells; however the effect of doxycycline was
much lower compared to the platinum compounds
(figure 1).
Combination Treatment
The combination treatment of doxycycline with plati-
num compounds in HT29 cells did not reveal any statis-
tically significant difference in the cytotoxicity compared
to the treatment of platinum compounds alone follow-
ing 24 hours of treatment (Figure 2).
Cytochrome c oxidase Staining
Cytochrome c oxidase activity staining showed a signifi-
cant lack of enzyme activity from day 3 onwards (Figure
3) in HT29 cells treated with doxycycline. Following the
results of this experiment, cytotoxicity and cell prolifera-
tion studies were performed after 3 days of doxycycline
treatment and they revealed statistically significant
increased cytotoxicity and anti-prolifetative effects in
HT29 cells after 3 days of doxycycline treatment com-
pared to 24 hours of treatment (Figure 4).
Pre-treatment of Doxycycline
The cytotoxicity studies reported that 3 days pre-treat-
ment of doxycycline enhanced the cytotoxic effects of
cisplatin and oxaliplatin in HT29 cancer cells signifi-
cantly compared to the treatment of platinum com-
pounds alone (figure 5). This difference in the
cytotoxicity was statistically significant.
Caspase 3 Expression and Activity
Caspase 3 gene expression studies revealed increased
caspase 3 gene expression in a time dependent manner
in HT29 cells treated with cisplatin and oxaliplatin, but
Figure 1 Dose response relationship of cisplatin, oxaliplatin and doxycycline.2×1 0
4 HT 29 cells/ml were treated with various
concentrations (1 to 1000 micromolar) of cisplatin, oxaliplatin and doxycycline (0.1 to 100 micrograms/ml) for 24 hours in the wells of 24 well
plates and the cytotoxicity measured with Alamar blue assay according to the manufacturer’s instructions. Control was taken as untreated cells.
Data are depicted as means of six experiments ± standard deviation.
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dent manner in the cells pre-treated with doxycycline
(figure 6). As these experiments were performed with
one-step RT-PCR (reverse transcription - polymerase
chain reation) method, to verify these findings, the real
time polymerase chain reactions (PCR) were used for
the assessment of caspase 3 gene expression. Real time
PCR showed similar findings to the results of RT PCR
(figure 7). Caspase 3 activity study showed time depen-
dent increase in caspase 3 activity in HT29 cells treated
with platinum compounds but there were no such trend
in HT29 cells pre-treated with doxycycline (figure 8).
Figure 2 Dose response relationship of combination treatment of doxycycline with platinum compounds.2×1 0
4 HT 29 cells/ml were
treated in the wells of 24 well plates with cisplatin or oxaliplatin with and without 10 μg/ml of doxycycline for 24 hours. The cytotoxicity was
assessed with Alamar blue assay according to the manufacturer’s instructions. Data are depicted as means of six experiments ± standard
deviation. (p = 0.84 for cisplatin and p = 0.95 for oxaliplatin experiments).
Figure 3 Cytochrome c oxidase activity.2×1 0
4 HT 29 cells were treated with 10 μg/ml of doxycycline over a period of 4 days and staining
for cytochrome c oxidase activity was performed as mentioned in methods. The brown staining is indicative of cytochrome c oxidase activity,
while purple staining is indicative of cell nucleus. Representative micrographs of six independent experiments are shown. Scale bar equals
20 μM.
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Colorectal cancer constitutes the third most common
cancer in UK. It is the second leading cause of cancer
deaths in UK. About one in 20 develops colorectal can-
cer in their lifetime. About 16,000 people are dying
from the colorectal cancer every year in UK (Cancer
Statistics, Cancer Research UK 2005). Three main thera-
peutic options available for colorectal cancer; Surgery,
Chemotherapy and Radiotherapy, are used either on
their own or in combinations. The main reasons for
mortality from colorectal cancer are metastases or
recurrence. Recently, doxycycline has been shown to
have MMPs inhibitory actions and thus has potential in
prevention of metastases[14]. Apart from being an anti-
biotic, doxycycline has been reported to have cytotoxic
actions and to suppress cell proliferation[14]. To date,
various studies have reported the apoptotic effects of
doxycycline in different cancers including prostate can-
cer[16], leukaemia[6], osteosarcoma[17] and pancreas
cancer[18]. However, precise mechanisms of apoptosis
are not well understood. Similarly, none of the work has
investigated the impact of doxycycline with other plati-
num agents in colorectal cancer. This study answered
whether doxycycline has any synergistic effects with pla-
tinum compounds; cisplatin and oxaliplatin, exploring
its potential use in colorectal cancer therapy.
Results of this study showed cisplatin, oxaliplatin and
doxycycline to be cytotoxic to HT 29 colorectal cancer
cells following 24 hours of treatment in a dose-depen-
dent manner; however, cisplatin and oxaliplatin were
more cytotoxic than doxycycline (figure 1). To rule out
any impact of serum in media, the cytotoxicity studies
Figure 4 Comparative cytotoxicity and anti-proliferative effects of doxycycline.2×1 0
4 HT 29 cells/ml were treated with doxycycline for
24 hours and 3 days in the wells of 6 well plates. The cytotoxicity and cell proliferation studies were performed with Alamar blue assay and
Picogreen assay according to the manufacturer’s instructions respectively. Data are depicted as means of six experiments ± standard deviation.
(* - Denotes statistically significant difference in the activity).
Figure 5 Pre-treatment of doxycycline.2×1 0
4 HT 29 cells/ml were treated with 10 μg/ml of doxycycline for 3 days in the wells of 6 well
plates followed by treatment with different concentrations of cisplatin and oxaliplatin for 24 hours. In similar settings, another set of experiments
was established without pre-treatment of doxycycline for 3 days. The cytotoxicity was assessed with Alamar blue assay according to the
manufacturer’s instructions. Data are depicted as means of six experiments ± standard deviation. (p = 0.003 for cisplatin and p = 0.003 for
oxaliplatin experiments). (* - Denotes statistically significant difference in the activity).
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was found that the drugs were more cytotoxic in media
containing serum, but this did not reach statistical sig-
nificance (data not shown) and therefore future experi-
ments were performed in the serum supplemented
media. The combination treatment of doxycycline and
platinum compounds in HT29 cells did not show any
statistically significant difference in the cytotoxicity
compared to cisplatin and oxaliplatin alone following 24
hours of treatments (figure 2). Thus in these initial
experiments, our study failed to show any synergistic
actions of doxycycline with platinum compounds. As
these combinations did not show any difference in the
cytotoxicity, the duration of treatment with doxycycline
necessary to decrease the threshold for the cytotoxic
effects of the cisplatin and oxaliplatin were looked in.
As cytochrome c oxidase (complex IV) plays significant
role in the oxidative phosphorylation of mitochondria
and doxycycline works by inhibition of mitochondrial
protein synthesis and thus inhibition of oxidative phos-
phorylation, cytochrome c oxidase activity was assessed
over a period of time following doxycycline treatment.
The cytochrome c oxidase activity reduced significantly
from day 3 onwards in HT 29 cells following treatment
Figure 6 Caspase 3 gene expression. Gel electrophoresis of GAPDH amplicons is displayed as control on the left side of figure. (CON =
Control, DOC = Doxycycline, CIS = Cisplatin, CD = Cisplatin and Doxycycline, OXA = Oxaliplatin, OD = Oxaliplatin and Doxycycline). The right
side of figure displays gel electrophoresis of caspase 3. (NC = Negative control, Con = CON = Positive control, Dox = DOX = Doxycycline, C(CIS)
1; C4; C24 = Cisplatin treatment for 1, 4 and 24 hours respectively, cd(CD)1; cd4; cd24 = Cisplatin and Doxycycline treatment for 1, 4 and
24 hours respectively, O(OXA)1; O4; O24 = Oxaliplatin treatment for 1, 4 and 24 hours respectively, od(OD)1; od4; 0d24 = Oxaliplatin and
Doxycycline treatment for 1, 4 and 24 hours respectively). Data are depicted as means of six experiments ± standard deviation. (* - Denotes
statistically significant difference in the activity).
Figure 7 Real time PCR for caspase 3 gene expression. This figure displays quantitative presentation of caspase 3 gene expression in HT
29 cells by real time PCR. (CON = control, DOX = doxycycline, CIS1; 4; 24 = Cisplatin treatment for 1, 4 and 24 hours respectively, CD1; 4; 24 =
Cisplatin and Doxycycline treatment for 1, 4 and 24 hours respectively, OXA1; 4; 24 = Oxaliplatin treatment for 1, 4 and 24 hours respectively,
OD1; 4; 24 = Oxaliplatin and Doxycycline treatment for 1, 4 and 24 hours respectively). Data are depicted as means of six experiments ±
standard deviation. (* - Denotes statistically significant difference in the activity).
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days treatment of doxycycline of HT 29 cells showed
significantly increased cytotoxic and anti-proliferative
effects compared to 24 hours of treatment (figure 4).
Thus it was decided to pre-treat HT 29 cells for 3 days
before the treatment of platinum compounds to assess
whether this would help to lower the apoptotic thresh-
old. The cytotoxicity studies following 3 day pre-treat-
ment of doxycycline revealed statistically significant
higher cytotoxicity compared to cisplatin or oxaliplatin
treatment alone (Figure 5). This suggested that doxycy-
cline lowered the apoptotic threshold in colorectal can-
cer cells for the cytotoxic actions of cisplatin and
oxaliplatin. Although doxycycline had shown apoptotic
lowering potential, the precise mechanism of this effect
was unclear. In an attempt to understand it, the caspase
studies were performed. Caspases are the cysteine pro-
teases and are crucial for the process of apoptosis. Cas-
pase 3 is one of the executioner caspases involved
towards the end of apoptotic induction following intrin-
sic as well as extrinsic pathways of apotptosis. Caspase
3 gene expression study revealed increased gene expres-
sion in a dose dependent manner in HT 29 cells treated
with cisplatin and oxaliplatin but there was no increase
in caspase 3 gene expression in the cells pre-treated
with doxycycline (figure 6). These findings were con-
firmed by another method for assessment of caspase 3
gene expression (real time PCR studies) (figure 7). In
order to verify these findings, it was decided to look at
caspase 3 activity in these cells. The caspase 3 activity
study reported similar findings to the caspase 3 gene
expression study (figure 8). The reduction in the cas-
pase 3 gene expression and activity in HT 29 cells pre-
treated with doxycycline might be due to the time
change in the measurement of gene expression and
activity. However, caspase-independent mechanisms of
apoptosis might be another explanation for these find-
ings as few studies reported caspase-independent
mechanisms of apoptosis in different cell lines[15].
Thus, this study suggested that pre-treatment of doxy-
cycline lowered the apoptotic threshold in HT 29 color-
ectal cancer cells which might be due to caspase-
independent mechanisms.
The advantage of doxycycline over other tetracyclines
is its longer duration of action and comparatively less
toxicity. Apart from cytotoxic and anti-proliferative
properties of doxycycline, the key finding in this experi-
ment was the inhibition of cytochrome c oxidase by
doxycycline which suggested involvement of mitochon-
dria in its actions. This study also suggests beneficial
role of doxycycline pre-treatment in enhancing the cyto-
toxic effects of cisplatin and oxaliplatin with possible
caspase independent mechanisms. As deficits or defects
in the apoptotic pathways are frequently present in the
Figure 8 Caspase 3 activity. This figure displays quantitative assessment of caspase 3 activity in HT 29 cells following drug treatments. (CON =
control, DOX = doxycycline, C1; 4; 24 = Cisplatin treatment for 1, 4 and 24 hours respectively, CD1; 4; 24 = Cisplatin and Doxycycline treatment
for 1, 4 and 24 hours respectively, O1; 4; 24 = Oxaliplatin treatment for 1, 4 and 24 hours respectively, OD1; 4; 24 = Oxaliplatin and Doxycycline
treatment for 1, 4 and 24 hours respectively). Data are depicted as means of six experiments ± standard deviation. (* - Denotes statistically
significant difference in the activity).
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Page 6 of 8tumours and are possible reasons for resistance to the
chemotherapeutic agents, doxycycline may be useful in
overcoming drug resistance however further research is
required to evaluate the precise role of doxycycline in
more detail before considering its potential use in clini-
cal trails.
Conclusions
We conclude that doxycycline may be useful as antipro-
liferative and cytotoxic agent and may be used to
improve the efficacy of cisplatin and oxaliplatin in color-
ectal cancer cells. However, further studies are needed
to clarify precise mechanisms of doxycycline in colorec-
tal cancer cells.
Methods
Cell line
The human colorectal cancer cell line, HT 29 (ECACC,
UK) was used in all experiments. The HT 29 cells were
maintained in McCoy 5A media supplemented with 10%
fetal bovine serum, penicillin (50 units/ml) and strepto-
mycin (50 units/ml) at 37°C in a humidified atmosphere
with 95% air and 5% CO2 .
Chemical reagents
Cisplatin (Bristol-Myers Squibb, UK), oxaliplatin
(Sanofi-Synthelabo, UK) and doxycycline (Alpharma,
UK) were used in this study.
Cell proliferation analysis
Cell proliferation was determined by Picogreen assay
(Qiagen, UK) according to manufacturer’s guidelines.
2×1 0
4 cells/ml HT 29 cells were plated in 6 well plates
and treated with 1, 5, 10, 50 and 100 micrograms/ml
(μg/ml) concentrations of doxycycline for 24 hours and
3 days respectively followed by cell proliferation studies.
Cytotoxicity analysis
Cytotoxicity of drugs was determined by Alamar blue
assay (Serotec, UK) according to manufacturer’sg u i d e -
lines. 2 × 10
4 cells/ml HT 29 cells were plated in 24
well plates and treated with different concentrations of
cisplatin, oxaliplatin and doxycycline for 24 hours fol-
lowed by cytotoxicity study. In similar settings, 2 × 10
4
cells/ml HT 29 cells were treated with combination of
10 μg/ml of doxcycline with different concentrations of
cisplatin and oxaliplatin for 24 hours followed by cyto-
toxicity assay. In another experiment, 2 × 10
4 cells/ml
HT 29 cells were plated in 6 well plates and treated
with doxycycline for 3 days followed by cytotoxicity
assay. In doxycycline pre-treatment experiment, 2 × 10
4
cells/ml HT 29 cells were plated in 6 well plates and
then treated with different concentrations of cisplatin
and oxaliplatin for 24 hours with or without 3 days pre-
treatment of 10 μg/ml doxycycline followed by cytotoxi-
city assay.
Cytochrome c oxidase activity
2×1 0
4 cells/ml HT 29 cells were plated on glass cover
slips in 6 well plates for 24 hours and then treated with
doxycycline over a period of 4 days. Cells were stained
with 3,3’ diaminobenzidine tetrahydrochloride (DAB)
(Sigma, UK) staining according to guidelines and cyto-
chrome c oxidase activity was visualised under a
microscope.
One Step RT-PCR and Real Time PCR for Caspase
3 gene expression
2×1 0
4 HT 29 cells/ml were cultured for 24 hours in
the wells of 6 well plates followed by 3 day treatment of
10 μg/ml of doxycycline. At the end of 3 days, the cells
were treated with different concentrations of cisplatin
and oxaliplatin for 1, 4 and 24 hours. After respective
treatment times, cells were trypsinized and cell pellets
were collected by centrifuging at 500 rounds per minute
(rpm) for 5 minutes. In a similar setting, the cells were
cultured but without pre-treatment of doxycycline and
at the end of day 3, cells were treated with cisplatin and
oxaliplatin alone. At 1, 4 and 24 hours of treatment, the
cell pellets were collected as mentioned earlier. The cell
pellets were preserved at -80°C. These cell pellets were
used for RNA extraction with the RNA-easy minikit
(QIAGEN, UK). One step RT PCR was performed for
caspase 3 gene expression using one-step RT PCR kit
(QIAGEN, UK) and real time PCR was performed using
two steps, first step of reverse transcription with the
Omniscript RT Kit (Qiagen, UK) followed by real time
PCR with Roche Molecular Lightcycler.
Caspase 3 activity
2×1 0
4 HT 29 cells/ml were cultured for 24 hours in
the wells of 6 well plates followed by 3 day treatment of
10 μg/ml of doxycycline. At the end of 3 days, the cells
were treated with different concentrations of cisplatin
and oxaliplatin for 1, 4 and 24 hours. After respective
treatment times, caspase 3 activity was assessed using
Caspase-3 Fluorometric Assay kit (R&D Systems, UK)
according to manufacture’s guidelines. In similar set-
tings, HT 29 cells were treated with cisplatin and oxali-
platin without any pre-treatment of doxycycline
followed by caspase 3 activity assays.
Statistical Analysis
The t test with two samples was performed for statisti-
cal analysis. The obtained p values were used for inter-
pretation of results. The p value of ≤ 0.05 was
considered statistically significant. For the purpose of
data analysis, the Microsoft XP system was used.
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